Evidence map›Paper›PMID 29117135›Full record

ArticleNanomaterials (Basel, Switzerland)2017

ZnO Nanoparticles Protect RNA from Degradation Better than DNA.

Jayden McCall, Joshua J Smith, Kelsey N Marquardt, Katelin R Knight, Hunter Bane, Alice Barber, Robert K DeLong

Open access · goldAbstract read
In one paragraph

Article in Nanomaterials (Basel, Switzerland), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Influence of chitosan coating on the oral bioavailability of gold nanoparticles in rats.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2019
    Article
  11. ZnO- and TiO₂-Based Nanostructures.Nanomaterials (Basel, Switzerland) · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Jayden McCallNanotechnology Innovation Center Kansas State (NICKS), Department of Anatomy and Physiology, College of Veterinary Medicine, Manhattan, KS 66506, USA. pcf17@ksu.edu.ORCID 0000-0001-6991-2022
Joshua J SmithDepartment of Biomedical Sciences, College of Health and Human Services, Missouri State University, Springfield, MO 65897, USA. JoshuaJSmith@MissouriState.edu.
Kelsey N MarquardtDepartment of Biomedical Sciences, College of Health and Human Services, Missouri State University, Springfield, MO 65897, USA. Marquardt410@live.missouristate.edu.
Katelin R KnightDepartment of Biomedical Sciences, College of Health and Human Services, Missouri State University, Springfield, MO 65897, USA. Katelin126@live.missouristate.edu.
Hunter BaneDepartment of Biomedical Sciences, College of Health and Human Services, Missouri State University, Springfield, MO 65897, USA. Bane3@live.missouristate.edu.
Alice BarberDepartment of Biomedical Sciences, College of Health and Human Services, Missouri State University, Springfield, MO 65897, USA. AliceBarber@UTA.edu.
Robert K DeLongNanotechnology Innovation Center Kansas State (NICKS), Department of Anatomy and Physiology, College of Veterinary Medicine, Manhattan, KS 66506, USA. robertdelong@ksu.edu.
Missouri State University · USKansas State University · US

Funding

Anti-Cancer RNA NanoconjugatesR15CA139390 · NCI · MISSOURI STATE UNIVERSITY · PI DELONG, ROBERT K., GARRAD, RICHARD C · 2009 to 2013
$640k
NCI NIH HHS R15 CA139390
6 · The paper itself

Abstract

Gene therapy and RNA delivery require a nanoparticle (NP) to stabilize these nucleic acids when administered in vivo. The presence of degradative hydrolytic enzymes within these environments limits the nucleic acids' pharmacologic activity. This study compared the effects of nanoscale ZnO and MgO in the protection afforded to DNA and RNA from degradation by DNase, serum or tumor homogenate. For double-stranded plasmid DNA degradation by DNase, our results suggest that the presence of MgO NP can protect DNA from DNase digestion at an elevated temperature (65 °C), a biochemical activity not present in ZnO NP-containing samples at any temperature. In this case, intact DNA was remarkably present for MgO NP after ethidium bromide staining and agarose gel electrophoresis where these same stained DNA bands were notably absent for ZnO NP. Anticancer RNA, polyinosinic-polycytidylic acid (poly I:C) is now considered an anti-metastatic RNA targeting agent and as such there is great interest in its delivery by NP. For it to function, the NP must protect it from degradation in serum and the tumor environment. Surprisingly, ZnO NP protected the RNA from degradation in either serum-containing media or melanoma tumor homogenate after gel electrophoretic analysis, whereas the band was much more diminished in the presence of MgO. For both MgO and ZnO NP, buffer-dependent rescue from degradation occurred. These data suggest a fundamental difference in the ability of MgO and ZnO NP to stabilize nucleic acids with implications for DNA and RNA delivery and therapy.

Indexed as

DNaseDNase activityDNA stabilitygel electrophoresismetal oxide nanoparticle (MONP)MgORNaseRNase activityRNA stabilityZnO

Identifiers

PMID29117135
PMCPMC5707595
OpenAlexW2767547822

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.